Company intelligence / Profile preview

Taichu Biotechnology

Shanghai, Shanghai, Chinataoisttaichi.org ↗

Ownership: Private
Development stage: Other

Overview

Taichu Biotechnology is an active Chinese CRO/CDMO founded in October 2020, specializing in non-clinical drug evaluation, antibody and chemical drug development, early screening for efficacy/toxicity/pharmacokinetics, and pilot/commercial manufacturing. It has established over 51 new methods for toxicology research, conducted more than 7,000 toxicological studies, and supported the development of over 3,000 new drugs globally. The company operates under GLP/GMP quality systems meeting international standards.

Modalities: Small moleculesAntibody drugsSmall nucleic acids
Industry: Contract Research Organization

Partnerships

Collaborates with global pharmaceutical companies as clients

Beyond the preview

Go deeper on Taichu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taichu Biotechnology.

Explore the full profile